This signaling network accounts for enhanced proliferation, chemotaxis, survival and drug resistance of CLL cells with high levels of ROR1, as well as for shorter median treatment-free survival relative to patients with lower levels of expression of ROR1 [138]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.